Table 1.
Findings reported and proportions of participants receiving high-risk information.
| Section of the report | How many received this info | High risk reported | ||
|---|---|---|---|---|
| N | % | N | % | |
| PRS and overall risk for T2D | 2916 | 98.6 | 569** | 19.5 |
| PRS for CHD and MI | 2916 | 98.6 | 559 | 19.2 |
| Early onset menopause PRS* | 2080 | 70.3 | 443 | 21.3 |
| Thrombophilia (F5, F2) | 2532 | 85.6 | 125 | 4.9 |
| α1-antitrypsin deficiency | 2531 | 85.6 | 92 | 3.6 |
| Carrier (cystic fibrosis) | 653 | 22.1 | 11 | 1.7 |
| Carrier (Wilson disease) | 2279 | 77.1 | 25 | 1.1 |
| Lactose intolerance associated genotype | 2956 | 100 | 786 | 26.6 |
| Exfoliation glaucoma risk | 2956 | 100 | 821 | 27.8 |
| ACMG findings (HBOC, CRC) | 666 | 22.5 | 22 | 3.3 |
| Pharmacogenomics | 2894 | 97.9 | 2834 | 97.9 |
*Women only; **T2D PRS only
PRS polygenic risk score, T2D type 2 diabetes, CHD coronary heart disease, MI myocardial infarction, F5 factor V, F2 factor II, ACMG American College of Medical Genetics and Genomics, HBOC hereditary breast and ovarian cancer, CRC colorectal cancer.